Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets

Vaccine

Volumn 29, Issue 11, 2011, Pages 2120-2126

  Baras, Benoît ^a   de Waal, Leon ^b   Stittelaar, Koert J ^b   Jacob, Valérie ^a   Giannini, Sandra ^a   Veldhuis Kroeze, Edwin J B ^b   van den Brand, Judith M A ^c   van Amerongen, Geert ^b   Simon, James H ^b   Hanon, Emmanuel ^a   Mossman, Sally P ^a   Osterhaus, Albert D M E ^b,c  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^b Viroclinics Biosciences BV   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

AS03; Ferret; H1N1; Vaccine

Indexed keywords

ALPHA TOCOPHEROL; INFLUENZA VACCINE;

2009 H1N1 INFLUENZA; ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; EMULSION; FEMALE; FERRET; INFLUENZA VACCINATION; MALE; NETHERLANDS; NONHUMAN; PRIORITY JOURNAL; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VIRUS REPLICATION; VIRUS SHEDDING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; FERRETS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; LUNG; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; VIRAL LOAD; VIRUS REPLICATION; VIRUS SHEDDING;

EID: 79951813743     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.125     Document Type: Article

References (30)

1. Fraser C., Donnelly C.A., Cauchemez S., Hanage W.P., Van Kerkhove M.D., Hollingsworth T.D., et al. Pandemic potential of a strain of influenza A (H1N1): early findings. Science 2009, 324(5934):1557-1561.
2. Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361(20):1945-1952.
3. Bresson J.-L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006, 367(9523):1657-1664.
4. Leroux-Roels I., Borkowski A., Vanwolleghem T., Dramé M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370(9587):580-589.
5. Leroux-Roels I., Bernhard R., Gérard P., Dramé M., Hanon E., Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 2008, 3(2):e1665.
6. Roman F., Vaman T., Gerlach B., Markendorf A., Gillard P., Devaster J.-M. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010, 28(7):1740-1745.
7. Hampson A.W. Ferrets and the challenges of H5N1 vaccine formulation. J Infect Dis 2006, 194(2):143-145.
8. Baras B., Stittelaar K.J., Simon J.H., Thoolen R.J.M.M., Mossman S.P., Pistoor F.H.M., et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 2008, 3(1):e1401.
9. Munster V.J., de Wit E., van den Brand J.M.A., Herfst S., Schrauwen E.J.A., Bestebroer T.M., et al. Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 2009, 325(5939):481-483.
10. van den Brand J.M.A., Stittelaar K.J., van Amerongen G., Rimmelzwaan G.F., Simon J., de Wit E., et al. Severity of pneumonia due to new H1N1 influenza virus in ferrets is intermediate between that due to seasonal H1N1 virus and highly pathogenic avian influenza H5N1 virus. J Infect Dis 2010, 201(7):993-999.
11. Del Giudice G., Stittelaar K.J., van Amerongen G., Simon J., Osterhaus A.D.M.E., Stöhr K., et al. Seasonal influenza vaccine provides priming for A/H1N1 immunization. Sci Trans Med 2009, 1(12):1-3.
12. Plennevaux E., Sheldon E., Blatter M., Reeves-Hoché M.-K., Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010, 375(9708):41-48.
13. Kreijtz J.H.C.M., Bodewes R., van den Brand J.M.A., de Mutsert G., Baas C., van Amerongen G., et al. Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus. Vaccine 2009, 27(36):4983-4989.
14. Kärber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Naunyn-Schmiedeberg's Arch Pharmacol 1931, 162(4):480-483.
15. Greenbaum J.A., Kotturi M.F., Kim Y., Oseroff C., Vaughan K., Salimi N., et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci USA 2009, 106(48):20365-20370.
16. Le L., Lee E., Schulten K., Truong T.N. Molecular modeling of swine influenza A/H1N1, Spanish H1N1, and avian H5N1 flu N1 neuraminidases bound to Tamiflu and Relenza. PLoS Curr Influenza 2009, RRN1015.
17. McElhaney J.E., Xie D., Hager W.D., Barry M.B., Wang Y., Kleppinger A., et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006, 176(10):6333-6339.
18. Rimmelzwaan G.F., Nieuwkoop N., Brandenburg A., Sutter G., Beyer W.E.P., Maher D., et al. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM™ vaccines and conventional vaccines. Vaccine 2001, 19(9-10):1180-1187.
19. Pashine A., Valiante N.M., Ulmer J.B. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005, 11(4 Suppl.):S63-S68.
20. Pinder M., Reece W.H.H., Plebanski M., Akinwunmi P., Flanagan K.L., Lee E.A.M., et al. Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS, S/AS02, in semi-immune adults in The Gambia. Clin Exp Immunol 2004, 135(2):286-293.
21. Reece W.H.H., Pinder M., Gothard P.K., Milligan P., Bojang K., Doherty T., et al. A CD4+ T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med 2004, 10(4):406-410.
22. Vandepapelière P., Rehermann B., Koutsoukos M., Moris P., Garçon N., Wettendorff M., et al. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults. Vaccine 2005, 23(20):2591-2601.
23. Ge X., Tan V., Bollyky P.L., Standifer N.E., James E.A., Kwok W.W. Assessment of seasonal influenza A specific CD4 T cell responses to 2009 pandemic H1N1 swine-origin influenza A virus. J Virol 2010, 84(7):3312-3319.
24. Leroux-Roels I., Leroux-Roels G. Current status and progress of prepandemic and pandemic influenza vaccine development. Expert Rev Vaccines 2009, 8(4):401-423.
25. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361(25):2405-2413.
26. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361(25):2424-2435.
27. Zhu F.-C., Wang H., Fang H.-H., Yang J.G., Lin X.J., Liang X.-F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361(25):2414-2423.
28. Arguedas A., Soley C., Lindert K. Responses to 2009 H1N1 vaccine in children 3 to 17 years of age. N Engl J Med 2010, 362(4):370-372.
29. Baras B., Stittelaar K.J., Kuiken T., Jacob V., Bernhard R., Giannini S., et al. Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets. Vaccine 2011, 29(11):2092-2099.
30. Leroux-Roels I., Roman F., Forgus S., Maes C., De Boever F., Dramé M., et al. Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010, 28(3):849-857.